Edition:
United States

Profile: BTG PLC (BTG.L)

BTG.L on London Stock Exchange

702.00GBp
12:05pm EDT
Change (% chg)

4.50 (+0.65%)
Prev Close
697.50
Open
694.00
Day's High
718.50
Day's Low
689.00
Volume
759,830
Avg. Vol
955,700
52-wk High
739.50
52-wk Low
528.36

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Company Address

BTG PLC

5 Fleet Place
LONDON     EC4M 7RD
P: +4420.75750000
F: +4420.75750010

Company Web Links